| Compounds | Topics | Title | Date |
|---|---|---|---|
| cannabis | adhd in humans via case study (n=1) | Cannabis improves symptoms of ADHD | 2008 |
| The present case report suggests that individuals suffering from ADHD, a dysfunction with a symptomatic change in activity levels, may - in some cases - benefit from cannabis treatment in that it appears to regulate activation to a level which may be considered optimum for performance. | |||
| cannabinoids | adhd,ptsd in vitro | Association of the Cannabinoid Receptor Gene (CNR1) With ADHD and Post-Traumatic Stress Disorder | Jun 2009 |
| These observations require replication, however, they suggest that the CNR1 gene may be a risk factor for ADHD and possibly PTSD, and that this gene warrants further investigation for a role in neuropsychiatric disorders. | |||
| WIN55 | adhd in rats via expertiment | The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. | Nov 2003 |
| These results support the notion that a reduced cortical density of cannabinoid CB1 receptors is associated with enhanced impulsivity. This behavioural trait can be positively modulated by administration of a cannabinoid agonist. Present results confirm and extend previous literature, indicating that adolescent SHRs represent a suitable animal model for the preclinical investigation of the early-onset ADHD syndrome. | |||
| cannabis | adhd in humans via survey (n=2811) | Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use. | Mar 2014 |
| When asked about the ADHD symptoms they have experienced when not using cannabis, a higher proportion of daily users met symptom criteria for an ADHD diagnoses of the subtypes that include hyperactive-impulsive symptoms than the inattentive subtype. For nondaily users, the proportions of users meeting symptom criteria did not differ by subtype. These results have implications for identifying which individuals with ADHD might be more likely to self-medicate using cannabis | |||
| Sativex | adhd in humans via placebo trial (n=30) | Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. | Aug 2017 |
|
Ingestion Method: Sativex Oromucosal Spray For the primary outcome, no significant difference was found in the ITT analysis although the overall pattern of scores was such that the active group usually had scores that were better than the placebo group (Est=-0.17, 95%CI-0.40 to 0.07, p=0.16, n=15/11 active/placebo). For secondary outcomes Sativex was associated with a nominally significant improvement in hyperactivity/impulsivity (p=0.03) and a cognitive measure of inhibition (p=0.05), and a trend towards improvement for inattention (p=0.10) and EL (p=0.11). Per-protocol effects were higher. | |||
| cannabis | adhd in humans via survey | Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality. | Jan 2019 |
| Using a two-sample Mendelian randomization approach we found support that ADHD is causal for lifetime cannabis use, with an odds ratio of 7.9 for cannabis use in individuals with ADHD in comparison to individuals without ADHD (95% CI (3.72, 15.51), P = 5.88 x 10-5) | |||
| THC | tourettes,adhd in humans via case study (n=1) | Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. | Apr 2010 |
| Our observation suggests that Delta 9-THC might be a successful alternative in patients with severe TS refractory to classic treatment. Particularly in the case of stimulant-induced exacerbation of tics, Delta 9-THC might enable successful treatment of comorbid ADHD. | |||